Nanoparticles as Budding Trends in Colon Drug Delivery for the Management of Ulcerative Colitis

Author(s): Amandeep Singh*, Kirandeep Kaur, Uttam Kumar Mandal, Raj Kumar Narang

Journal Name: Current Nanomedicine
Formerly Recent Patents on Nanomedicine

Volume 10 , Issue 3 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Inflammatory Bowel Disease (IBD) is a disorder of the gastrointestinal tract, which is characterized by Crohn’s disease and Ulcerative colitis. Ulcerative colitis (UC) is a chronic idiopathic relapsing colon disease distinguishes by the interference of epithelial wall and colonic site tenderness. For the treatment of ulcerative colitis, various side effects have been reported, due to the non-specific delivery of the targeted drug of the conventional system. This review will explain the reader about various considerations for the preparation of orally administered NPs drug delivery systems for the treatment of ulcerative colitis. Moreover, principles and novel strategies for colon targeting based on the physiology of colon so that the tract of gastro intestine can be used as the identification marker for a target site for drugs. Besides this, the role of phytomedicines in controlling and managing the ulcerative colitis has been discussed. Additionally, the major problem for the smart delivery of NPs in clinical applications with their difficulties in Intellectual Property Rights (IPR) was also discussed. Finally, this review provides various potential approaches to NPs for the treatment of UC.

Keywords: Colon targeted drug delivery, identification markers, nanoparticles, ulcerative colitis, Inflammatory Bowel Disease (IBD), Crohn’s disease.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 10
ISSUE: 3
Year: 2020
Published on: 05 November, 2020
Page: [225 - 247]
Pages: 23
DOI: 10.2174/2468187310999200621200615
Price: $65

Article Metrics

PDF: 7